Patents by Inventor Amy Gentry

Amy Gentry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Edg receptor agonists
    Patent number: 7479504
    Abstract: The present invention encompasses compounds of Formula 1: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: January 20, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Robert L. Bugianesi, George A. Doherty, Amy Gentry, Jeffrey J. Hale, Christopher L. Lynch, Sander G. Mills, William E. Neway, III
  • Pyrrolidine modulators of CCR5 chemokine receptor activity
    Patent number: 7125887
    Abstract: Pyrrolidine compounds of Formula (I), (wherein R1, R2, R3, R4, R5, R6a, R6b, R7 and R8 are defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: October 24, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Jeffrey J. Hale, Charles G. Caldwell, Dooseop Kim, Dong-Ming Shen, Sander G. Mills, Kevin T. Chapman, Liya Chen, Malcolm MacCoss, Amy Gentry, Christopher L. Lynch, Yuan Cheng, legal representative, Christopher A. Willoughby, deceased
  • Edg receptor agonists
    Publication number: 20050033055
    Abstract: The present invention encompasses compounds of Formula 1: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
    Type: Application
    Filed: January 15, 2003
    Publication date: February 10, 2005
    Inventors: Robert Bugianesi, George Doherty, Amy Gentry, Jeffrey Hale, Christopher Lynch, Sander Mills, William Neway III
  • Pyrrolidine modulators of ccr5 chemokine receptor activity
    Publication number: 20040087552
    Abstract: Pyrrolidine compounds of Formula (I), (wherein R1, R2, R3, R4, R5, R6a, R6b, R7 and R8 are defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Application
    Filed: July 17, 2003
    Publication date: May 6, 2004
    Inventors: Jeffrey J Hale, Charles G. Caldwell, Dooseop Kim, Dong-Ming Shen, Sander G. Mills, Kevin T. Chapman, Liya Chen, Malcolm MacCoss, Amy Gentry, Christopher L. Lynch, Christopher A. Willoughby, Yuan Cheng
  • Pyrrolidine modulators of CCR5 chemokine receptor activity
    Publication number: 20020094989
    Abstract: Pyrrolidine compounds of Formula I: 1
    Type: Application
    Filed: October 10, 2001
    Publication date: July 18, 2002
    Inventors: Jeffrey J. Hale, Christopher L. Lynch, Charles G. Caldwell, Christopher A. Willoughby, Dooseop Kim, Dong-Ming Shen, Sander G. Mills, Kevin T. Chapman, Liya Chen, Amy Gentry, Malcolm MacCoss, Zenon D. Konteatis